Phase III trial of oral ALZ 801 in patients with early Alzheimer's disease

4 June 2021
alzheon_large

Privately-held US neurology specialist Alzheon today announced the dosing of the first patient in its APOLLOE4 Phase III study evaluating the efficacy and safety of ALZ-801 in early AD patients carrying two copies of the ε4 allele of the apolipoprotein E gene (APOE4/4 homozygotes).

AD patients with this genetic profile present with an early onset and rapid progression of the disease and are responsive to drug agents that remove or inhibit pathogenic amyloid oligomers. ALZ-801 is an oral treatment that has been shown in pre-clinical mechanistic studies to fully inhibit the formation of neurotoxic soluble beta amyloid oligomers at the Phase III clinical dose.

Alzheon’s announcement comes just ahead of the much-anticipated upcoming US Food and Drug Administration decision on Biogen’s (Nasdaq: BIIB) aducanumab, the most advanced AD candidate, which is expected on Monday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology